HAVCR2 and breast cancer: Another clinical study involving BC patients showed that the combination of sabatolimab (MBG453, an anti-TIM-3 monoclonal antibody) and spartalizumab (an anti-PD-1 monoclonal antibody) was well tolerated and exhibited early signs of antitumor activity [143].